Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Subcutaneous Exparel in Healthy Chinese Subjects
NCT04158102Phase 1Completed
- Sponsor
- Nuance Pharma
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupivacaine in Persistent postsurgical pain (PPSP), sponsored by Nuance Pharma. Primary endpoints: Plasma concentration up to 14 days and Area under the plasma concentration-versus-time curve up to 14 days. Started Nov 2019; status: completed.
02
Drugs
bupivacaine
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT04158102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158102.